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Atrial fibrillation (AF) is a common arrhythmia in heart failure (HF) and presents a significant 
risk factor for thromboembolic stroke. Despite recommendations in best practice guidelines, 
implementation of risk stratification, therapeutic approaches for AF and thromboprophylaxis are 
not uniformly applied in practice.  
 
Purpose 
This study aims to identify both barriers and enablers to thromboprophylaxis in patients with 
HF and AF as a concomitant condition at the levels of the patient, provider and health system.  
 
Methods 
This was undertaken through a series of discrete studies, including: (1) a prospective cohort 
study of individuals with HF and AF at St Vincent’s Hospital, Sydney; (2) bedside interviews 
with patients, and medical file note review; and (3) an electronic survey of cardiovascular 







Patient level: Results of this research demonstrate that patient choice and preference were 
important factors in thromboprophylaxis decisions, including treatment burden, unfavorable or 
intolerable side effects and patient refusal. Facilitators to successful prescription and adherence 
were caregiver support, reminders and routine, self-testing and the use of technology. At a 
health system level, financial barriers included cost of travel; medication cost and 
reimbursement were important considerations. 
Provider level: Survey findings revealed mixed levels of education on AF, stroke risk, 
anticoagulation and health behavior modification. The CHA2DS2VASc and HAS-BLED risk 
stratification tools were reported to be underused. Nurses reported key barriers to 
anticoagulation to include; fears of patients falling, fears of poor adherence to medication taking 
and routine monitoring. Additionally, patient self-monitoring and self-management were 
reported to be underutilized. Cardiovascular nurses reported their key role to be counselling and 
advising patients on therapy regimens. Anticoagulant-drug interaction knowledge was generally 
poor.  From the medical file note review, clinician reticence included fear of falls, frailty, age, 
fear of bleeding and the challenges of multi-morbidity. Psychological factors included 
psychiatric illness, cognitive impairment and depression. Social barriers included homelessness 
and the absence of a caregiver or lack of caregiver assistance.  The cohort study revealed that 
66% of participants were prescribed an anticoagulant at discharge from hospital. Self-reported 
self-care behavior and ‘not for CPR’ were associated with not receiving anticoagulation at 
discharge. Whilst statistical significance was not achieved, those who were assessed as frail or 
having greater comorbidity, were less likely to receive anticoagulation at discharge from 






1. Treatment decisions must be tailored to meet the needs of individuals, whilst balanced in the 
context of the best available evidence.  
2. There is need to formalize the role of the caregiver in the management of AF and CHF. 
3. Improved focus on AF within existing chronic care programs is warranted, given the aging 
population.  
4. Developing quality patient education materials and self-management strategies are key 
priority areas for enhancing sustainable models of care. 
5. There is scope for improvement in nurses’ knowledge and practice in contemporary AF 
management.  
6. Patient preference, choice and attributes must be considered when making complex 







The findings of this thesis point to the need for patient-centered approaches to the management 
of AF in the setting of HF, as well as increased skills and competencies for nurses. This thesis 
demonstrates that although stroke and bleeding risk calculation are important there are other 
salient considerations in making clinical decisions for thromboprophylaxis including cognitive 
impairment, multimorbidity, self-care ability and frailty. These factors not only influence 
decision making on the part of provider and patient but also influence clinical outcomes. Shared 
decision making provides a framework for patients and providers to have quality 
communication, negotiate consensus and find agreements on treatment goals. These findings 
underscore the need for shared decision making when making complex treatment decisions 
around thromboprophylaxis. 
